Biorestorative Therapies, Inc. (NASDAQ:BRTX) Short Interest Down 35.8% in February

Biorestorative Therapies, Inc. (NASDAQ:BRTX) saw a large decrease in short interest during the month of February. As of February 27th, there was short interest totaling 787,086 shares, a decrease of 35.8% from the February 12th total of 1,226,671 shares. Based on an average daily volume of 18,567,889 shares, the days-to-cover ratio is currently 0.0 days. Approximately 12.6% of the company’s stock are short sold. Approximately 12.6% of the company’s stock are short sold. Based on an average daily volume of 18,567,889 shares, the days-to-cover ratio is currently 0.0 days.

Biorestorative Therapies Stock Down 1.7%

Shares of NASDAQ BRTX opened at $0.30 on Friday. The firm’s 50-day moving average price is $0.72 and its 200-day moving average price is $1.15. The company has a market cap of $2.74 million, a PE ratio of -0.21 and a beta of 0.47. Biorestorative Therapies has a 52-week low of $0.19 and a 52-week high of $2.10.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Biorestorative Therapies in a report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Biorestorative Therapies currently has an average rating of “Sell”.

Institutional Investors Weigh In On Biorestorative Therapies

Hedge funds have recently added to or reduced their stakes in the stock. DRW Securities LLC bought a new position in shares of Biorestorative Therapies during the 4th quarter valued at $55,000. Citadel Advisors LLC purchased a new position in shares of Biorestorative Therapies in the 3rd quarter worth $152,000. Finally, Virtu Financial LLC grew its holdings in shares of Biorestorative Therapies by 102.4% in the third quarter. Virtu Financial LLC now owns 24,351 shares of the company’s stock worth $35,000 after acquiring an additional 12,319 shares during the period. 69.38% of the stock is currently owned by hedge funds and other institutional investors.

About Biorestorative Therapies

Biorestorative Therapies Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment.

Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy.